These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Unraveling the Complex Story of Immune Responses to AAV Vectors Trial After Trial. Vandamme C; Adjali O; Mingozzi F Hum Gene Ther; 2017 Nov; 28(11):1061-1074. PubMed ID: 28835127 [TBL] [Abstract][Full Text] [Related]
23. Distinct immune responses to transgene products from rAAV1 and rAAV8 vectors. Lu Y; Song S Proc Natl Acad Sci U S A; 2009 Oct; 106(40):17158-62. PubMed ID: 19805176 [TBL] [Abstract][Full Text] [Related]
24. Enhancing transduction of the liver by adeno-associated viral vectors. Nathwani AC; Cochrane M; McIntosh J; Ng CY; Zhou J; Gray JT; Davidoff AM Gene Ther; 2009 Jan; 16(1):60-9. PubMed ID: 18701909 [TBL] [Abstract][Full Text] [Related]
25. Immunity to adeno-associated virus vectors in animals and humans: a continued challenge. Zaiss AK; Muruve DA Gene Ther; 2008 Jun; 15(11):808-16. PubMed ID: 18385765 [TBL] [Abstract][Full Text] [Related]
26. Regulatory and Exhausted T Cell Responses to AAV Capsid. Gernoux G; Wilson JM; Mueller C Hum Gene Ther; 2017 Apr; 28(4):338-349. PubMed ID: 28323492 [TBL] [Abstract][Full Text] [Related]
27. T Cell-Mediated Immune Responses to AAV and AAV Vectors. Ertl HCJ Front Immunol; 2021; 12():666666. PubMed ID: 33927727 [TBL] [Abstract][Full Text] [Related]
28. Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors. Manning WC; Zhou S; Bland MP; Escobedo JA; Dwarki V Hum Gene Ther; 1998 Mar; 9(4):477-85. PubMed ID: 9525309 [TBL] [Abstract][Full Text] [Related]
29. Ocular Inflammatory Response to Intravitreal Injection of Adeno-Associated Virus Vector: Relative Contribution of Genome and Capsid. Timmers AM; Newmark JA; Turunen HT; Farivar T; Liu J; Song C; Ye GJ; Pennock S; Gaskin C; Knop DR; Shearman MS Hum Gene Ther; 2020 Jan; 31(1-2):80-89. PubMed ID: 31544533 [TBL] [Abstract][Full Text] [Related]
30. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Mingozzi F; High KA Blood; 2013 Jul; 122(1):23-36. PubMed ID: 23596044 [TBL] [Abstract][Full Text] [Related]
31. Adeno-Associated Viruses (AAV) and Host Immunity - A Race Between the Hare and the Hedgehog. Rapti K; Grimm D Front Immunol; 2021; 12():753467. PubMed ID: 34777364 [TBL] [Abstract][Full Text] [Related]
32. Preclinical models to assess the immunogenicity of AAV vectors. Ertl HCJ Cell Immunol; 2019 Aug; 342():103722. PubMed ID: 29195742 [TBL] [Abstract][Full Text] [Related]
33. Adeno-associated virus (AAV) vectors in gene therapy: immune challenges and strategies to circumvent them. Hareendran S; Balakrishnan B; Sen D; Kumar S; Srivastava A; Jayandharan GR Rev Med Virol; 2013 Nov; 23(6):399-413. PubMed ID: 24023004 [TBL] [Abstract][Full Text] [Related]
34. Immunogenicity and toxicity of AAV gene therapy. Ertl HCJ Front Immunol; 2022; 13():975803. PubMed ID: 36032092 [TBL] [Abstract][Full Text] [Related]
35. Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy. Wang Z; Allen JM; Riddell SR; Gregorevic P; Storb R; Tapscott SJ; Chamberlain JS; Kuhr CS Hum Gene Ther; 2007 Jan; 18(1):18-26. PubMed ID: 17176210 [TBL] [Abstract][Full Text] [Related]
36. Mapping the structural determinants responsible for enhanced T cell activation to the immunogenic adeno-associated virus capsid from isolate rhesus 32.33. Mays LE; Wang L; Tenney R; Bell P; Nam HJ; Lin J; Gurda B; Van Vliet K; Mikals K; Agbandje-McKenna M; Wilson JM J Virol; 2013 Sep; 87(17):9473-85. PubMed ID: 23720715 [TBL] [Abstract][Full Text] [Related]
37. Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Martino AT; Basner-Tschakarjan E; Markusic DM; Finn JD; Hinderer C; Zhou S; Ostrov DA; Srivastava A; Ertl HC; Terhorst C; High KA; Mingozzi F; Herzog RW Blood; 2013 Mar; 121(12):2224-33. PubMed ID: 23325831 [TBL] [Abstract][Full Text] [Related]
39. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. Jooss K; Yang Y; Fisher KJ; Wilson JM J Virol; 1998 May; 72(5):4212-23. PubMed ID: 9557710 [TBL] [Abstract][Full Text] [Related]
40. Challenges Posed by Immune Responses to AAV Vectors: Addressing Root Causes. Hamilton BA; Wright JF Front Immunol; 2021; 12():675897. PubMed ID: 34084173 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]